Conference Correspondent

Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens.

Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated, BRCA-wildtype ovarian cancer patients.

This combination of antiangiogenic and immune checkpoint blockade has clinical activity in women with recurrent ovarian cancer.

Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support.

The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile.

Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer.

Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer.

Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies.

Early intervention and supportive care for gastrointestinal and hepatic toxicities should be considered for patients receiving PARP inhibitors.

Analysis of high-grade serous ovarian cancers suggests that BRCA1/2-driven cancers have a more favorable mode of relapse than sporadic cancers.